Mibrex (Rivaroxaban)

Rivaroxaban works by selectively inhibiting factor Xa, a crucial enzyme in the coagulation cascade. By blocking factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and limiting the formation of fibrin clots.

The dose of Mibrex is individualized by the prescribing clinician based on the specific indication, the patient’s renal and hepatic function, age, weight, and any concomitant medications that may affect bleeding risk. No fixed regimen is provided here.

Safety data for rivaroxaban during pregnancy and lactation are limited. It is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and the decision should be made by a qualified healthcare professional.

To order Mibrex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mibrex (rivaroxaban) offers fixed dosing without routine laboratory monitoring, a rapid onset of action, and fewer food and drug interactions compared with warfarin. Warfarin requires regular INR testing and has numerous dietary restrictions, but it remains an option for patients with certain contraindications to direct factor Xa inhibitors.

Mibrex should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability.

Mibrex is taken orally as a tablet. The tablet should be swallowed whole with water and can be taken with or without food, according to the prescriber’s instructions.

The most serious risks include major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, spinal or epidural hematoma, and severe allergic reactions. Patients should be monitored for signs of bleeding and advised to seek immediate medical attention if they experience unusual bruising, blood in stool or urine, or severe headache.

Mibrex is contraindicated in patients with active major bleeding, severe hepatic impairment, or those who have a known hypersensitivity to rivaroxaban. Caution is also advised for individuals with uncontrolled hypertension, recent major surgery, or a history of intracranial hemorrhage.